Cytokine-based therapeutic angiogenesis from the bench to clinical trials has been a major focus of medical research, and the efficacy of vascular endothelial growth factor (VEGF) blockers has led to the approval of anti-angiogenesis drugs for cancer and eye disease. Here, VEGFA is linked to cancer.